M-M-RVaxPro (measles, mumps and rubella vaccine (live))
- Region
- 🇪🇺 EU
- Active substance
- measles, mumps and rubella vaccine (live)
- Company
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- Therapeutic area
- Rubella; Mumps; Immunization; Measles
- CHMP opinion
- Thu 23 Feb 2006
- EU approval
- Fri 05 May 2006
- Application
- EMEA/H/C/000604
- ATC
- J07BD52
- Official record
- www.ema.europa.eu
Indication
M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older. For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 ProQuad Authorised · Merck Sharp & Dohme B.V.
Follow M-M-RVaxPro
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.